HIV vaccine knowledge and beliefs among communities at elevated risk: Conspiracies, questions and confusion

Journal of the National Medical Association

Volumn 97, Issue 12, 2005, Pages 1662-1671

  Roberts, Kathleen Johnston ^a   Newman, Peter A ^d   Duan, Naihua ^b   Rudy, Ellen T ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Neuropsychiatric Institute   (United States)

^c Los Angeles County   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

African Americans; Conspiracy theories; HIV vaccines; HIV AIDS; IV drug users; Latinos; Qualitative research

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICAN AMERICAN; ARTICLE; CONFUSION; FEMALE; HIGH RISK PATIENT; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; PATIENT EDUCATION; PRIORITY JOURNAL; PRIVATE PRACTICE; QUALITATIVE ANALYSIS; VACCINATION;

ADOLESCENT; ADULT; AFRICAN AMERICANS; AIDS VACCINES; CLINICAL TRIALS; CONFUSION; FEMALE; FOCUS GROUPS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HISPANIC AMERICANS; HIV INFECTIONS; HUMANS; INTERVIEWS; LOS ANGELES; MALE; MIDDLE AGED; PATIENT EDUCATION; PATIENT SELECTION; QUALITATIVE RESEARCH; RISK FACTORS;

EID: 28644449366     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Holmberg SD. The estimated prevalence and incidence of HIV in 96 large U.S. metropolitan areas. Am J Public Health. 1990;86:642-654.
2. UNAIDS/WHO. Joint United Nations Programme on HIV/AIDS and World Health Organization, AIDS epidemic update. December 2003. Geneva, Switzerland: UNAIDS, 2003.
3. Mantell J, Myer L, Carballo-Dieguez A, et al. Microbicide acceptability research: current approaches and future directions. Soc Sci Med. 2005;60: 319-330.
4. Levy J. What can be achieved with an HIV vaccine? Lancet. 2001; 9251:223-224.
5. Newman PA, Duan N, Rudy ET, et al. Post-trial HIV vaccine adoption: concerns, motivators and intentions among persons at risk for HIV. J Acquir Immune Defic Syndr. 2004;37:1393-1403.
6. Esparza J, Chang ML, Widdus R, et al. Estimation of "needs" and "probable uptake" for HIV/AIDS preventive vaccines based on possible policies and likely acceptance (a WHO/UNAIDS/IAVI study). Vaccine. 2003;21:2041-2050.
7. Newman PA, Duan N, Rudy ET, et al. HIV vaccine dissemination and clinical trial participation: If we build it will they come? AIDS Patient Care STDs. 2004;18:7-17.
8. Bojak A, Deml L, Wagner R. The past, present and future of HIV-vaccine development: a critical view. Drug Discoveries Today. 2002;7:36-46.
9. Edgeworth RL, San JH, Rosenzweig JA, et al. Vaccine development against HIV-1: current perspectives and future directions. Immunology Research. 2002;25:53-74.
10. Cohen J. Vaccine results lose significance under scrutiny. Science. 2003;299:1495.
11. Vaxgen announces results of its phase-III HIV vaccine trial in Thailand: vaccine fails to meet endpoints. Nov. 12, 2003. www.vaxgen.com/pressroom/index. html. Accessed 11/05/05.
12. Francis DP, Heyward WL, Popovic V, et al. Candidate HIV/AIDS vaccines: lessons learned from the world's first phase-III efficacy trial. AIDS. 2003;17:147-156.
13. Johnston M, Flores J. Progress in HIV vaccine development. Curr Opin Pharmacol. 2001;1:504-510.
14. Future access to HIV vaccines. Report from a WHO-UNAIDS Consultation, Geneva: October 2-3, 2000. AIDS. 2001;15:W27-44.
15. Hu DJ, Vitek CR, Bartholow B, et al. Key issues for a potential human immunodeficiency virus vaccine. Clin Infect Dis. 2003;36:638-644.
16. Koblin BA, Heagerty P, Sheon A, et al. Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States. AIDS. 1998;12:785-793.
17. Koblin BA, Holte S, Lenderking B, et al. Readiness for HIV vaccine trials: changes in willingness and knowledge among high-risk populations in the HIV network for prevention trials. The HIVNET Vaccine Preparedness Study Protocol Team. J Acquir Immune Defic Syndr. 2000;24:451-457.
18. McGrath JW, George K, Svilar G, et al. Knowledge about vaccine trials and willingness to participate in an HIV/AIDS vaccine study in the Ugandan military. J Acquir Immune Defic Syndr. 2001;27:381-388.
19. Liau A, Zimet GD. The acceptability of HIV immunization: examining vaccine characteristics as determining factors. AIDS Care. 2001;13:643-650.
20. Zimet GD, Fortenberry JD, Blythe MJ, Adolescents' attitudes about HIV immunization. J Pediatr Psychol. 1999;24:67-75.
21. Celentano DD, Beyrer C, Natpratan C, et al. Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand. AIDS. 1995;9:1079-1083.
22. Morgan DL. The Focus Group Guidebook. Thousand Oaks, CA: Sage Publications; 1998.
23. Lincoln YS, Guba EG. Naturalistic Inquiry. Newbury Park, CA: Sage Publications; 1985.
24. Strauss A, Corbin J. Basics of Qualitative Research: Grounded Theory Procedures and Techniques. Newbury Park, CA: Sage Publications; 1990.
25. Newman PA, Duan N, Rudy ET, et al. HIV risk and prevention in a post-vaccine context. Vaccine. 2004;22:1954-1963.
26. Singleton R, Straits BC. Approaches to Social Research. New York, NY: Oxford University Press; 1999.
27. Guinan ME. Black communities' belief in "AIDS as genocide": A barrier to overcome for HIV prevention. Ann Epidemiol. 1993;3:193-195.
28. Klonoff EA, Landrine H. Do blacks believe that HIV/AIDS is a government conspiracy against them? Prev Med. 1999;28:451-457.
29. Bogart LM, Bird ST. Exploring the relationship of conspiracy beliefs about HIV/AIDS to sexual behaviors and attitudes among African-American adults. J Natl Med Assoc. 2003;95(11):1057-1065.
30. Bogart LM, Thorburn S. Are HIV/AIDS conspiracy beliefs a barrier to HIV prevention among African Americans? J Acquir Immune Defic Syndr. 2005;2:213-218.
31. Herek GM, Capitanio JP. Conspiracies, contagion and compassion. AIDS Educ Prev. 1994;6:365-375.
32. Jones JH. Bad blood: The Tuskegee syphilis experiment. New York, NY: The Free Press; 1982.
33. Thomas SB, Quinn SC. The Tuskegee Syphilis Study, 1932 to 1972: implications for HIV education and AIDS risk education programs in the black community. Am J Public Health. 1991;81:1498-1505.
34. Bates BF, Harris TM. The Tuskegee Study of Untreated Syphilis and public perceptions of biomedical research: a focus group study. J Natl Med Assoc. 2004;96:1051-1064.
35. Corbie-Smith G, Thomas SB, St. George DM. Distrust, race and research. Arch Intern Med. 2002;162:2458-2463.
36. Freimuth VS, Quinn SC, Thomas SB, et al. African Americans' views on research and the Tuskegee Syphilis Study. Soc Sci Med. 2001;52:797-808.
37. Shavers VL, Lynch CF, Burmeister LF. Knowledge of the Tuskegee study and its impact on the willingness to participate in medical research studies. J Natl Med Assoc. 2000;92:563-572.
38. Herek GM, Capitanio JP, Widaman KF. HIV-related stigma and knowledge in the United States: prevalence and trends, 1991-1999. Am J Public Health. 2002;92:371-377.
39. World Health Organization. Expanded programme on immunization (EPI): lack of evidence that hepatitis B vaccine causes multiple sclerosis. Wkly Epidemiol Rec. 1997;72:149-152.
40. Institute of Medicine. Immunization safety review: measles-mumps-rubella vaccine and autism. Washington, DC: Institute of Medicine National Academy Press; 2002.
41. Walensky RP, Paltiel AD, Goldie SJ, et al. A therapeutic HIV vaccine: how good is good enough? Vaccine. 2004;22:4044-4053.
42. Haynes BF. Scientific and social issues of human immunodeficiency virus vaccine development. Science. 1993;260:1279-1286.
43. Johnston R. AIDSVAX results: An answer, or just more questions? AIDS Patient Care STD. 2003;17:4751.
44. Anderson RM, Garnett GP. Low-efficacy HIV vaccines: potential for community-based intervention programmes. Lancet. 1996;348:1010-1013.
45. Blower SM, McLean AR. Prophylactic vaccines, risk behavior change and the probability of eradicating HIV in San Francisco. Science. 1994;265:1451-1454.
46. Daniels NA, Juarbe T, Rangel-Lugo M, et al. Focus group interviews on racial and racial/ethnic attitudes regarding vaccinations. J Natl Med Assoc. 2004;96:1455-1461.
47. Cummings KM, Becker MH, Maile MC. Bringing the models together: An empirical approach to combining variables used to explain health actions. J Behav Med. 1980;3:123-145.
48. Isarena S, Kamolratanakul P, Sakulramrung R. Factors influencing acceptance of hepatitis B vaccination by hospital personnel in an area hyperendemic for hepatitis B. Am J Gastroenterol. 1992;87:1807-1818.
49. Rudy ET, Douglas W, Detels R, et al. Factors affecting hepatitis A and B vaccination refusal in a sexually transmitted disease clinic that primarily serves men who have sex with men. Sex Transm Dis. 2003;30:411-418.
50. Halpern SD, Metzger DS, Berlin JA, et al. Who will enroll? Predicting participation in a phase-II AIDS vaccine trial. J Acquir Immune Defic Syndr. 2001;27:281-288.
51. Gifford AL, Cunningham W, Heslin KC, et al. Participation in research and access to experimental treatments by HIV-infected patients. N Engl J Med. 2002;346:1373-1382.
52. Smith KY, Orgain J, Scott R. Disparities and gaps in HIV research and care. J Natl Med Assoc. 2004;96:5S-7S.
53. Freeman VA, Freed GL. Parental knowledge, attitudes and demand regarding a vaccine to prevent varicella. Am J Prev Med. 1999;17:153-155.